Introduction Immunocompromised patients with B-cell depletion agents are at risk for
persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID …

Objectives The aim of the study was to describe a cohort of B-cell-depleted
immunocompromised (IC) patients with prolonged or relapsing COVID-19 treated with …

Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs
the adaptive immune response, causing severe manifestations during COronaVIrus Disease …

SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

Objective Patients with immune‐mediated inflammatory diseases (IMIDs) receiving B cell–
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …

We report a lymphoma patient with profound B-cell deficiency after chemotherapy combined
with anti-CD20 antibody successfully treated with remdesivir and convalescent plasma for …

Patients with genetic and acquired humoral immunodeficiencies present with an atypical
course of coronavirus disease 2019 (COVID-19). Persistent viral shedding with multiple viral …

B cell-targeting strategies such as rituximab are widely used in B cell hematologic
malignancies, rheumatologic and musculoskeletal diseases and a variety of autoimmune …

A 59-year-old male with follicular lymphoma treated by anti-CD20-mediated B-cell depletion
and ablative chemotherapy was hospitalized with a COVID-19 infection. Although the patient …

We described three critically ill patients with coronavirus disease 2019 (COVID-19) in
Wuhan, China, featured with profound inflammation and treated with blood purification …